DexCom, Inc. (DXCM.O)
7.13USD
8 Dec 2009
$-0.17 (-2.33%)
$7.30
$7.23
$7.32
$7.13
385,837
271,241
$8.96
$2.17
DXCM.O
About
Overall
| Beta: | 1.48 |
| Market Cap (Mil.): | $336.03 |
| Shares Outstanding (Mil.): | 46.03 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| DXCM.O | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 3.84 | 4.63 |
| EPS (TTM): | 27.12 | -- | -- |
| ROI: | -154.73 | 2.78 | 2.80 |
| ROE: | -- | 4.38 | 4.09 |
US RESEARCH SUMMARY-Non-S&P 500 Nov 11 1650 GMT
Following is a summary of research actions on non-S&P 500
UPDATE 1-DexCom Q3 misses analysts' expectations
posted a wider-than-expected quarterly loss as
New devices help control diabetes better - study
WASHINGTON (Reuters) - Devices that constantly monitor blood sugar levels of people with diabetes help them control their glucose better than the old-fashioned method of pricking their fingers throughout the day, researchers reported on Monday.
New devices help control diabetes better: study
WASHINGTON (Reuters) - Devices that constantly monitor blood sugar levels of people with diabetes help them control their glucose better than the old-fashioned method of pricking their fingers throughout the day, researchers reported on Monday.
Dexcom says gets FDA OK to calibrate glucose monitoring system
Nov 16 (Reuters) - DexCom Inc said it has received approval to calibrate its seven-day continuous glucose monitoring system using any blood glucose meter cleared by the Food and Drug Administration. DexCom said with the approval patients will be able to calibrate the system without using a connection cable.
UPDATE 1-Analyst note on diabetes monitor inaccurate-Abbott
LOS ANGELES, Nov 8 (Reuters) - Abbott Laboratories said on Thursday it is not ending its Navigator Continuous Glucose Monitor Program or initiating layoffs in its diabetes division after an analyst said in a client note that such actions were in the works.
DexCom Q3 results
DEXCOM INC : * Third quarter per share loss $0.40 * Third quarter revenue rose 45 percent to $1.2 million * Reuters Estimates third quarter per share view $-0.40, revenue view $1.23 million
DexCom CFO retires, interim replacement named
July 30 (Reuters) - Medical device maker DexCom Inc. said its Chief Financial Officer Steven Kemper retired effective July 31 to pursue other opportunities.
TABLE-DexCom Q2 net loss widens
DEXCOM INC. (in $) Latest Yr-ago qtr Loss/shr (diluted) 0.40 0.41 Net loss (million) 11.3 11.2 Revenue (thousands) 863 479 Reuters Estimates: Loss/shr $0.41, revenue $1.2 million. (Reporting by Manish Gupta in Bangalore)
Vasogen names Waddick CEO
NEW YORK, June 20 (Reuters) - Biotechnology company Vasogen Inc. said on Wednesday it has named Chris Waddick as President and Chief Executive.
Competitors
| Price | Change | |
|---|---|---|
| Roche Holding Ltd. (ROG.VX) | CHF168.10 | -0.60 |
| Johnson & Johnson (JNJ.N) | $64.25 | -0.12 |
| Abbott Laboratories (ABT.N) | $53.24 | -0.42 |
| Bayer AG (BAYGn.DE) | €52.09 | -0.91 |
| Bayer AG (BAYE.F) | -- | -- |
| Medtronic, Inc. (MDT.N) | $42.79 | -0.27 |
| Pfizer Inc. (PFE.N) | $17.76 | -0.30 |
| GlaxoSmithKline plc (GSK.L) | £1,293.00 | -10.50 |
| Novartis AG (NOVN.VX) | CHF56.65 | -0.20 |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
